Tempus AI, Inc. (TEM) · Oct 23, 2026 · Material agreement
$192.5M data agreement — BMS $137.5M fixed plus Pathos up to $55M over approximately five years
Tempus AI expands its BMS and Pathos data agreements to $192.5 million, strengthening pharma demand while spreading payments and delivery risk over five years.
Tempus is building a higher-growth data and applications business alongside its diagnostics operation, with recent momentum coming from oncology data licensing and AI tools for drug development; in Q2, the company said Data Licensing & Modeling revenue rose 36% year over year and that it had signed roughly $200 million of new Data and Applications licenses.
The filing converts that strategy into a large, multi-year commercial commitment. The BMS oncology agreement adds de-identified multimodal records, Lens software access, and research services, while the Pathos agreement extends Tempus’s data and agentic analysis tools into neurology and BMS’s therapeutic-development work. The two agreements together provide for $192.5 million of cash payments over approximately five years.
| Agreement | Customer structure | Economics | Timing / delivery |
|---|---|---|---|
| Onco SOW | BMS | $137.5M fixed payments | Quarterly through December 31, 2031 |
| Neuro Order Form | Pathos, with sublicense rights to BMS | Up to $55M: $50M for delivered records plus $5M for updates | 500,000 neurology records over five years |
The quality of the revenue is better than a one-off data sale, but it is not $192.5 million of near-term revenue. The BMS oncology payments are fixed and invoiced quarterly, providing visibility. The neurology component is conditional on Tempus delivering the records, so its $55 million ceiling is not guaranteed. 〔0〕
The main tradeoff is limited exclusivity around the neurology data. Tempus cannot license the applicable records to third parties during the specified protection period, which may restrict near-term reuse of some data even as the BMS relationship validates demand for Tempus’s multimodal datasets and agentic tools. The Pathos transactions were also reviewed by a special committee because of related-party overlap, reducing the governance ambiguity but not changing the economics.
Bottom line: This is a meaningful expansion of Tempus’s pharma-data commercialization story and adds substantial contracted demand beyond diagnostics. It matters positively, but the financial impact builds gradually and depends partly on execution and record delivery rather than arriving upfront.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!